News & Views

Telix Pharmaceuticals Limited is pleased to announce the establishment Telix Pharmaceuticals (Japan) Ltd and appointment of the first two members of the Japanese leadership team.

Telix has today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK)

Telix has today announced the appointment of Dr. Bernard Lambert as President and Chief Operating Officer (COO) of Telix’s US subsidiary.

Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.

Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA (ANMI).

Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50 million.

Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of Melbourne.

Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public Offering.

Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology (VisAcT).

Telix is pleased to announce today that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of Telix Pharmaceuticals Limited as Non-Executive Directors.